Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ionis Pharmaceuticals Says Topline Results From The Pivotal Study Of Zilganersen For Alexander Disease Showed Statistically Significant And Clinically Meaningful Stabilization On The Primary Endpoint Of Gait Speed Compared To Control

Author: Benzinga Newsdesk | September 22, 2025 07:07am

First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition.
NDA submission planned in Q1 2026

Posted In: IONS